PUBLISHER: DelveInsight | PRODUCT CODE: 1048318
PUBLISHER: DelveInsight | PRODUCT CODE: 1048318
DelveInsight's, "TIL Therapy - Pipeline Insight, 2022" report provides comprehensive insights about 30+ companies and 30+ pipeline drugs in TIL Therapy pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
TIL Therapy Understanding
TIL Therapy: Overview
TIL (tumor-infiltrating lymphocyte) therapy is a type of cellular immunotherapy that may be used to treat head and neck squamous cell carcinoma, melanoma, lung cancer, genitourinary cancers and a growing list of other malignancies. TIL therapy essentially uses altered tumor cells to destroy the tumor itself. TILs, or tumor-infiltrating lymphocytes, are special immune system cells (T cells) that are naturally present inside some tumors. In TIL therapy, TILs are collected from the tumor during a biopsy, or surgical resection, and grown to very large numbers in a laboratory with interleukin-2 (IL-2), a protein that promotes rapid TIL growth. Once successfully grown to billions in number, the TILs are infused back into the patient, where they actively attack cancer cells while leaving healthy cells alone.
"TIL Therapy - Pipeline Insight, 2022" report by DelveInsight outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the TIL Therapy pipeline landscape is provided which includes the disease overview and TIL Therapy treatment guidelines. The assessment part of the report embraces, in depth TIL Therapy commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, TIL Therapy collaborations, licensing, mergers and acquisition, funding, designations and other product related details.
TIL Therapy Emerging Drugs Chapters
This segment of the TIL Therapy report encloses its detailed analysis of various drugs in different stages of clinical development, including phase II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.
TIL Therapy Emerging Drugs
The TIL therapy under investigation in Phase II clinical trial, lifileucel (formerly LN-145), is expanded and rejuvenated TIL that was extracted from the patient's own tumor. Lifileucel is an investigational therapy that is being tested in clinical studies for the treatment of Recurrent, Metastatic or Persistent Cervical Carcinoma.
ITIL-68 has been designed to improve the scalability, logistics, and accessibility of TIL therapy. The drug is currently in phase I stage of development for the treatment of patients with Melanoma.
Further product details are provided in the report……..
TIL Therapy: Therapeutic Assessment
This segment of the report provides insights about the different TIL Therapy drugs segregated based on following parameters that define the scope of the report, such as:
There are approx. 30+ key companies which are developing the therapies for TIL Therapy. The companies which have their TIL Therapy drug candidates in the most advanced stage, i.e. phase II include, Ivonace Biotherapeutics.
DelveInsight's report covers around 30+ products under different phases of clinical development like
TIL Therapy pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as
Products have been categorized under various Molecule types such as
Drugs have been categorized under various product types like Mono, Combination and Mono/Combination.
TIL Therapy: Pipeline Development Activities
The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses TIL Therapy therapeutic drugs key players involved in developing key drugs.
Pipeline Development Activities
The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging TIL Therapy drugs.
Key Questions
Current Treatment Scenario and Emerging Therapies:
Introduction
Executive Summary
TIL Therapy: Overview
Pipeline Therapeutics
Therapeutic Assessment
TIL Therapy - DelveInsight's Analytical Perspective
In-depth Commercial Assessment
TIL Therapy Collaboration Deals
Mid Stage Products (Phase II)
LN-145: Ivonace Biotherapeutics
Drug profiles in the detailed report…..
Early Stage Products (Phase I)
ITIL-168: Instil Bio
Drug profiles in the detailed report…..
Inactive Products
TIL Therapy Key Companies
TIL Therapy Key Products
TIL Therapy- Unmet Needs
TIL Therapy- Market Drivers and Barriers
TIL Therapy- Future Perspectives and Conclusion
TIL Therapy Analyst Views
TIL Therapy Key Companies
Appendix